Relief And Rebuke For Biocon In Herceptin Biosimilars Case
This article was originally published in Scrip
Executive Summary
An Indian court did not hold back the launch of Biocon's biosimilar version of Roche's Herceptin (trastuzumab) for two additional indications - early breast cancer and metastatic gastric cancer - but had some tough words against the Bengaluru-based firm on its apparent "conduct" in obtaining regulatory approval of the carton, labels and the package insert.
You may also be interested in...
Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs
An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).
Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs
An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.